- Home
- SISI vs MBIO Comparison
SISI vs MBIO Comparison
Compare SISI & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- MBIO
- Stock Information
- Founded
- SISI 1997
- MBIO 2015
- Country
- SISI China
- MBIO United States
- Employees
- SISI N/A
- MBIO N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- MBIO Health Care
- Exchange
- SISI Nasdaq
- MBIO Nasdaq
- Market Cap
- SISI 4.0M
- MBIO 4.7M
- IPO Year
- SISI 2016
- MBIO N/A
- Fundamental
- Price
- SISI $0.17
- MBIO $2.49
- Analyst Decision
- SISI
- MBIO
- Analyst Count
- SISI 0
- MBIO 0
- Target Price
- SISI N/A
- MBIO N/A
- AVG Volume (30 Days)
- SISI 3.1M
- MBIO 17.5M
- Earning Date
- SISI 05-15-2025
- MBIO 08-12-2025
- Dividend Yield
- SISI N/A
- MBIO N/A
- EPS Growth
- SISI N/A
- MBIO N/A
- EPS
- SISI N/A
- MBIO N/A
- Revenue
- SISI $9,601,324.00
- MBIO N/A
- Revenue This Year
- SISI N/A
- MBIO N/A
- Revenue Next Year
- SISI N/A
- MBIO N/A
- P/E Ratio
- SISI N/A
- MBIO N/A
- Revenue Growth
- SISI 1133.26
- MBIO N/A
- 52 Week Low
- SISI $0.15
- MBIO $0.89
- 52 Week High
- SISI $28.32
- MBIO $24.00
- Technical
- Relative Strength Index (RSI)
- SISI 30.10
- MBIO 59.93
- Support Level
- SISI $0.15
- MBIO $2.62
- Resistance Level
- SISI $0.19
- MBIO $3.68
- Average True Range (ATR)
- SISI 0.03
- MBIO 0.59
- MACD
- SISI 0.01
- MBIO 0.15
- Stochastic Oscillator
- SISI 26.75
- MBIO 27.30
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.